Peptide Therapy: A Comprehensive Guide

Key Takeaways

• Peptides are short chains of amino acids that act as targeted signaling molecules, instructing cells to grow, heal, regulate hormones, support immunity, or balance appetite.
• VIMC prescribes peptides for weight management (GLP-1 agonists such as semaglutide and tirzepatide), tissue repair and recovery (BPC-157, TB-500), body composition and growth hormone support (Sermorelin, CJC-1295/Ipamorelin), hormonal balance (gonadorelin), immune support (Thymosin Alpha-1), and sexual health (PT-141).
• VIMC only uses prescription-grade peptides made for human consumption through trusted compounding pharmacies; peptide availability is subject to evolving FDA regulations, and unregulated sources carry real safety risks.
• Most peptides produce subtle cumulative effects over weeks to months rather than dramatic transformations, and work best as one tool in a broader integrative plan that includes foundational hormone, thyroid, gut, and lifestyle work.
• Peptide therapy is typically cash-pay and not covered by insurance, with monthly costs ranging from approximately $150 to $500 depending on the specific peptide and dosing protocol.

Peptide therapy has moved from the edges of integrative medicine into the mainstream conversation about weight management, recovery, hormone optimization, and healthy aging. The GLP-1 medications that have reshaped weight management are themselves peptides, and many patients arrive at VIMC asking what else this category offers and whether peptides are right for them. The honest answer is that some peptides have meaningful clinical utility in the right context, others are oversold online, and the regulatory landscape has shifted significantly since 2023. This guide separates the signal from the noise.

At Venus Integrative Medical Center (VIMC) in Mesa, Arizona, peptide therapy is offered selectively, prescribed only in contexts where the clinical evidence supports use, sourced through credible compounding pharmacies that maintain quality standards, and built into broader treatment plans rather than offered as standalone solutions. This guide walks through what peptides are, which categories are part of modern integrative practice, what the regulatory landscape currently looks like, and how VIMC approaches peptide therapy responsibly.

What are Peptides?

Peptides are short chains of amino acids, the building blocks of proteins. The body produces hundreds of natural peptides that act as signaling molecules: telling cells to grow, repair tissue, modulate inflammation, regulate appetite, release hormones, or coordinate immune function. Therapeutic peptides are synthesized to mimic or amplify these natural signals.

This is fundamentally different from broad-spectrum drugs that act on multiple systems at once. A well-chosen peptide can deliver a specific physiological signal: stimulate growth hormone release, support tissue repair, modulate appetite signaling, or influence immune balance. The targeted nature is part of what makes peptide therapy appealing to integrative practitioners, and part of why it requires careful prescribing and oversight.

The FDA Regulatory Landscape (as of 2026)

The regulatory environment for compounded peptides has changed meaningfully since 2023. The FDA placed several peptides on Category 2 of its compounded substances list, which restricts traditional and outsourcing compounding pharmacies from preparing them under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Some peptides remain widely available through legitimate compounding channels, others have become harder to access, and the picture continues to shift as additional review proceeds.

VIMC's approach in this environment is straightforward: VIMC only uses prescription-grade peptides made for human consumption, sourced through trusted compounding pharmacies. The types of peptides available are subject to FDA regulations and may change as the regulatory landscape evolves. Patients should be wary of peptides sourced from research-chemical websites, social media sellers, or unlicensed providers, which are not held to medical-grade quality standards and carry real safety risks.

Peptide Categories Used in Integrative Practice

Peptides fall into several broad clinical categories. The categories below reflect peptides that are part of integrative practice, with regulatory and quality considerations noted where relevant.

Metabolic and weight-related peptides

GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are FDA-approved peptide medications that have reshaped weight management and type 2 diabetes care. They work by enhancing satiety, slowing gastric emptying, and improving insulin sensitivity. The 2023 SELECT trial (Lincoff et al., NEJM) of more than 17,000 patients with obesity and established cardiovascular disease but no diabetes found that weekly semaglutide reduced major adverse cardiovascular events by 20 percent over roughly 40 months of follow-up. This was the first GLP-1 cardiovascular outcomes trial in a non-diabetic population. VIMC prescribes GLP-1 medications when clinically appropriate, paired with the nutrition, body composition, and lifestyle work that produces sustainable results.

AOD-9604 is a synthetic peptide fragment derived from human growth hormone that has been studied for its potential effects on fat metabolism. The regulatory status of compounded AOD-9604 has shifted in recent years, and availability depends on the compounding pharmacy.

Growth hormone-releasing peptides

Sermorelin is a peptide that stimulates the pituitary gland to produce and release growth hormone. It has been used clinically for growth hormone deficiency and is also prescribed in integrative practice for body composition, recovery, and sleep. Sermorelin remains commercially available and has been part of compounding practice for years.

CJC-1295 and Ipamorelin are also growth hormone-releasing peptides used in integrative practice for similar indications. Their regulatory status has shifted since 2023, and current availability through compounding pharmacies depends on individual pharmacy decisions and ongoing FDA review. When prescribed, VIMC sources through credible compounders and discusses the regulatory context with patients during informed consent.

Healing and tissue repair peptides

BPC-157 is a synthetic peptide derived from a protein found in gastric juice, studied for its potential effects on tendon, ligament, and gut healing. TB-500 is a synthetic fragment of thymosin beta-4, used clinically for tissue repair and recovery. Both have moved into a more restricted regulatory status since 2023; patients interested in these peptides should expect a candid conversation about current availability and quality sourcing.

Skin, hair, and connective tissue peptides

GHK-Cu (copper peptide) is a naturally occurring peptide associated with collagen synthesis, wound healing, and skin remodeling. It is used in both injectable and topical formulations in integrative practice. As with several peptides in this category, regulatory status of compounded preparations has shifted, and current availability depends on the compounding pharmacy.

Hormonal support peptides

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH) that stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In integrative practice, gonadorelin is used to support endogenous testosterone production and preserve fertility, particularly in men on or considering TRT. It serves a similar functional role to hCG and clomiphene but works upstream at the pituitary level. Kisspeptin, another GnRH-axis peptide, is currently awaiting FDA release for compounding.

Sexual health peptides

PT-141 (bremelanotide) is a melanocortin receptor agonist that supports sexual desire and arousal through central nervous system pathways rather than vascular mechanisms. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women under the brand name Vyleesi, and is used in selected patients beyond that specific indication when clinically appropriate.

Immune-modulating peptides

Thymosin Alpha-1 is a peptide derived from the thymus gland and used clinically to support immune function in selected patients. It has been used internationally for several decades and remains part of integrative practice. As with other peptides in this overview, current sourcing through credible compounding pharmacies is essential.

How VIMC Approaches Peptide Therapy

Peptide therapy is not a default first-line intervention at VIMC. It is one tool among many, considered in the context of a comprehensive evaluation that has already addressed hormone status, thyroid function, gut health, nutrient deficiencies, sleep, and lifestyle. Patients who arrive expecting peptides as a quick fix typically benefit more from establishing the foundations first; patients for whom peptides are appropriate often see better outcomes precisely because the surrounding clinical picture has been addressed.

Three principles anchor the approach. First, indication matters more than novelty. A peptide is prescribed when it addresses a specific clinical question with reasonable evidence, not because it is trending. Second, sourcing matters more than price. Only credible compounding pharmacies that operate within current regulatory parameters and maintain documented quality standards are used. Third, monitoring matters more than initiation. Peptides are integrated into broader plans with follow-up labs, symptom tracking, and dose adjustments rather than prescribed and forgotten.

Safety, Risks, and Realistic Expectations

Peptides are not free of risk. Injection-site reactions, immune sensitization to specific peptides, and unpredictable individual response are all possible. The risk of poor-quality compounded product is real and is one of the reasons sourcing through a credible pharmacy matters. Long-term safety data for many peptides remain limited compared with longer-established medications.

Realistic expectations are also part of responsible care. Most peptides produce subtle, cumulative effects rather than dramatic transformations. Patients who experience meaningful benefit usually do so over weeks to months, paired with the lifestyle and foundational work that supports the underlying physiology. Marketing claims that promise rapid, dramatic results from a single peptide deserve skepticism.

Who Is And Is Not a Candidate for Peptide Therapy?

Good candidates typically include adults who have addressed foundational hormone, thyroid, gut, and lifestyle work and are looking to optimize specific areas (recovery, body composition, sleep, immune function) within a comprehensive plan. Patients managing weight where GLP-1 medications are appropriate often benefit when peptides are paired with structured nutrition and movement work.

Patients who are not appropriate candidates include those with active cancer or recent malignancy without oncology guidance, pregnancy or breastfeeding, certain autoimmune conditions in flare, or known sensitivity to specific peptides. Each peptide has its own specific contraindications, which are reviewed during evaluation and informed consent.

Ready to Have a Real Conversation About Peptide Therapy?

If you have been reading about peptides and wondering whether they are appropriate for your situation, the answer depends entirely on the clinical picture. The VIMC team approaches peptide therapy as one tool in a broader integrative plan, prescribed selectively when the evidence supports use and the foundational work has been done. Schedule a consultation to talk through where peptides may, or may not, belong in your care.